Synjardy

Congestive Heart Failure, Physical Activity, Monotherapy + 8 more
Treatment
6 FDA approvals
20 Active Studies for Synjardy

What is Synjardy

EmpagliflozinThe Generic name of this drug
Treatment SummaryMetformin is a medication used to treat type 2 diabetes. It is the first-line drug of choice for managing type 2 diabetes and is taken by more than 120 million people around the world. Metformin lowers blood sugar levels without causing hypoglycemia, increases insulin sensitivity, and leads to modest weight loss. It was first approved in Canada in 1972 and in the United States in 1995. Metformin is available in regular and extended-release form.
Jardianceis the brand name
image of different drug pills on a surface
Synjardy Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Jardiance
Empagliflozin
2014
24

Approved as Treatment by the FDA

Empagliflozin, also called Jardiance, is approved by the FDA for 6 uses including Type 2 Diabetes Mellitus and Physical Activity .
Type 2 Diabetes Mellitus
Used to treat Type 2 Diabetes Mellitus in combination with Metformin
Physical Activity
Used to treat Exercise in combination with Metformin
Type 2 Diabetes
Used to treat Type 2 Diabetes Mellitus in combination with Metformin
Diet
Used to treat Diet in combination with Metformin
Cardiovascular Diseases
Cardiovascular Mortality

Effectiveness

How Synjardy Affects PatientsInsulin is a hormone that helps control the amount of sugar in the blood. People with Type II diabetes have a decreased sensitivity to insulin, which means their pancreas cannot keep up with regulating their sugar levels. Metformin works to reduce the amount of sugar produced by the liver and absorbed by the intestines, as well as increase the body's sensitivity to insulin. In a clinical trial, people taking Metformin had decreased fasting blood sugar levels by an average of 59 mg/dL, while those taking a placebo had increased levels by 6.3 mg/dL. Metformin also decreased HbA1c by 1
How Synjardy works in the bodyMetformin works in several ways to reduce blood glucose levels. It decreases the amount of glucose produced in the liver, decreases the amount of glucose absorbed from food in the intestines, and makes cells more sensitive to insulin. Metformin enters liver cells through a transporter called OCT1, and accumulates in the mitochondria. It blocks the production of energy in the mitochondria, turning on an enzyme called AMPK. This helps to decrease fat production and increase fat burning, as well as reduce glucose production in the liver. In the intestines, metformin increases anaerobic glucose metabolism, leading to less net glucose uptake and

When to interrupt dosage

The suggested dose of Synjardy is contingent upon the recognized disorder, including Diet, inadequate response to metformin and Diabetic Ketoacidosis. The quantity differs, in line with the methodology of delivery (e.g. Oral or Tablet - Oral) listed in the table below.
Condition
Dosage
Administration
Cardiovascular Diseases
10.0 mg, 25.0 mg, , 5.0 mg, 12.5 mg
Tablet, Tablet - Oral, Oral, , Tablet, film coated, Tablet, film coated - Oral, Tablet, extended release, Tablet, extended release - Oral
Type 2 Diabetes
10.0 mg, 25.0 mg, , 5.0 mg, 12.5 mg
Tablet, Tablet - Oral, Oral, , Tablet, film coated, Tablet, film coated - Oral, Tablet, extended release, Tablet, extended release - Oral
Diet
10.0 mg, 25.0 mg, , 5.0 mg, 12.5 mg
Tablet, Tablet - Oral, Oral, , Tablet, film coated, Tablet, film coated - Oral, Tablet, extended release, Tablet, extended release - Oral
Cardiovascular Mortality
10.0 mg, 25.0 mg, , 5.0 mg, 12.5 mg
Tablet, Tablet - Oral, Oral, , Tablet, film coated, Tablet, film coated - Oral, Tablet, extended release, Tablet, extended release - Oral
Heart Failure
10.0 mg, 25.0 mg, , 5.0 mg, 12.5 mg
Tablet, Tablet - Oral, Oral, , Tablet, film coated, Tablet, film coated - Oral, Tablet, extended release, Tablet, extended release - Oral
Therapeutic procedure
10.0 mg, 25.0 mg, , 5.0 mg, 12.5 mg
Tablet, Tablet - Oral, Oral, , Tablet, film coated, Tablet, film coated - Oral, Tablet, extended release, Tablet, extended release - Oral
Ejection fraction decreased
10.0 mg, 25.0 mg, , 5.0 mg, 12.5 mg
Tablet, Tablet - Oral, Oral, , Tablet, film coated, Tablet, film coated - Oral, Tablet, extended release, Tablet, extended release - Oral
Hospitalizations
10.0 mg, 25.0 mg, , 5.0 mg, 12.5 mg
Tablet, Tablet - Oral, Oral, , Tablet, film coated, Tablet, film coated - Oral, Tablet, extended release, Tablet, extended release - Oral
Congestive Heart Failure
10.0 mg, 25.0 mg, , 5.0 mg, 12.5 mg
Tablet, Tablet - Oral, Oral, , Tablet, film coated, Tablet, film coated - Oral, Tablet, extended release, Tablet, extended release - Oral
Physical Activity
10.0 mg, 25.0 mg, , 5.0 mg, 12.5 mg
Tablet, Tablet - Oral, Oral, , Tablet, film coated, Tablet, film coated - Oral, Tablet, extended release, Tablet, extended release - Oral
Monotherapy
10.0 mg, 25.0 mg, , 5.0 mg, 12.5 mg
Tablet, Tablet - Oral, Oral, , Tablet, film coated, Tablet, film coated - Oral, Tablet, extended release, Tablet, extended release - Oral

Warnings

Synjardy Contraindications
Condition
Risk Level
Notes
Kidney Failure
Do Not Combine
Renal Dialysis
Do Not Combine
Severe Hypersensitivity Reactions
Do Not Combine
Empagliflozin may interact with Pulse Frequency
There are 20 known major drug interactions with Synjardy.
Common Synjardy Drug Interactions
Drug Name
Risk Level
Description
Acetazolamide
Minor
Empagliflozin may increase the diuretic activities of Acetazolamide.
Ambrisentan
Minor
Empagliflozin may increase the hypotensive activities of Ambrisentan.
Amiloride
Minor
Empagliflozin may increase the diuretic activities of Amiloride.
Angiotensin 1-7
Minor
Empagliflozin may increase the hypotensive activities of Angiotensin 1-7.
Azosemide
Minor
Empagliflozin may increase the diuretic activities of Azosemide.
Synjardy Toxicity & Overdose RiskThe toxic dose of metformin in rats is 1000mg/kg when taken orally, 500mg/kg when given through the abdomen, and 300mg/kg when injected under the skin. The toxic dose in mice is 1450mg/kg orally, 420mg/kg through the abdomen, and 225mg/kg when injected under the skin. Taking too much metformin can lead to lactic acidosis, a serious condition where too much acid builds up in the blood. Risk factors for lactic acidosis include kidney problems, being over 65 years old, taking certain medications, drinking too much alcohol, or having liver disease
image of a doctor in a lab doing drug, clinical research

Synjardy Novel Uses: Which Conditions Have a Clinical Trial Featuring Synjardy?

346 active trials are assessing the potential of Synjardy in treating Type 2 Diabetes, Type 1 Diabetes and inadequate response to Metformin therapy.
Condition
Clinical Trials
Trial Phases
Type 2 Diabetes
168 Actively Recruiting
Not Applicable, Phase 1, Phase 2, Phase 3, Phase 4, Early Phase 1
Cardiovascular Diseases
0 Actively Recruiting
Congestive Heart Failure
187 Actively Recruiting
Not Applicable, Phase 1, Phase 2, Phase 4, Phase 3, Early Phase 1
Hospitalizations
1 Actively Recruiting
Not Applicable
Monotherapy
1 Actively Recruiting
Phase 1, Phase 2
Heart Failure
0 Actively Recruiting
Diet
5 Actively Recruiting
Not Applicable, Phase 1
Therapeutic procedure
0 Actively Recruiting
Ejection fraction decreased
0 Actively Recruiting
Physical Activity
24 Actively Recruiting
Not Applicable, Phase 1, Phase 2
Cardiovascular Mortality
0 Actively Recruiting

Synjardy Reviews: What are patients saying about Synjardy?

5Patient Review
10/17/2018
Synjardy for Type 2 Diabetes Mellitus
Synjardy has been great for me. I brought my A1C down from 10.6 to 6.0 in a year, and experienced zero negative side effects.
4Patient Review
4/17/2016
Synjardy for Type 2 Diabetes Mellitus
4Patient Review
11/9/2017
Synjardy for Type 2 Diabetes Mellitus
2.3Patient Review
1/30/2019
Synjardy for Type 2 Diabetes Mellitus
My A1C rose from 6.5 to 8.7 after my doctor switched me from Farxiga to Synjardy. I found the latter drug much less effective than the former.
2Patient Review
9/4/2018
Synjardy for Type 2 Diabetes Mellitus
I unfortunately got a yeast infection from this medication.
1.7Patient Review
5/12/2019
Synjardy for Type 2 Diabetes Mellitus
Thirst, yeast infection, and constant trips to the bathroom are all unfortunately common side effects of this medication. I've been taking it for five months now and have had to deal with a lot of discomfort as a result.
1Patient Review
9/9/2018
Synjardy for Type 2 Diabetes Mellitus
I was worried from the start with this prescription. My blood sugar shot up, and even when I increased the dose as directed, it didn't seem to be effective.
1Patient Review
9/8/2021
Synjardy for Type 2 Diabetes Mellitus
I was in a lot of pain after injuring my knee and was prescribed Synjardy. However, this medication caused me more pain and fatigue than the original injury. I stopped taking it and felt better the next day.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about synjardy

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is Synjardy used for?

"This medication is a combination of 2 drugs: empagliflozin and metformin. It is used with a proper diet and exercise program to lower blood sugar in people with type 2 diabetes. Controlling blood sugar helps prevent kidney damage, blindness, nerve problems, loss of limbs, and sexual function problems."

Answered by AI

What is the side effects of Synjardy?

"Some possible causes of these symptoms include low blood sugar, a urinary tract infection, a stuffy or runny nose and sore throat, yeast infections in females, diarrhea, nausea or vomiting, gas, stomach discomfort, indigestion, weakness, or a headache."

Answered by AI

What is the difference between Synjardy and metformin?

"Synjardy contains both metformin and the drug empagliflozin. Metformin lowers blood sugar levels through several mechanisms, and the addition of empagliflozin provides additional blood sugar lowering effects."

Answered by AI

Are Jardiance and Synjardy the same thing?

"Jardiance is a medication used to treat type 2 diabetes. It is available as a standalone tablet or as a combination tablet with metformin. The medication works by helping the body to better use insulin. Side effects may include nausea, diarrhea, and headaches. Jardiance is a brand-name medication and costs can vary depending on insurance coverage."

Answered by AI

Clinical Trials for Synjardy

Image of University of California, Los Angeles in Los Angeles, United States.

Tailored DPP for Prediabetes

17 - 25
All Sexes
Los Angeles, CA
The goal of this study is to enhance reach and uptake of diabetes prevention among young adults, with a focus on recruiting underserved and high-need students who face additional challenges, including food and financial insecurity. The specific aims are: Aim 1 - Evaluate the efficacy of an AYA-tailored version of the UC DPP for mitigating type 2 diabetes risk (i.e., weight change) in a pre/post pilot trial. The investigators hypothesize that the AYA-tailored intervention will be effective at producing 5% weight loss from baseline to program completion (at 9-months). Aim 2 - Assess the feasibility and acceptability of an AYA-tailored version of the UC DPP program. The investigators hypothesize that it will be feasible to recruit the desired number of participants given proposed innovative outreach strategies, and that the AYA-tailored intervention will be deemed acceptable to participants both qualitatively and in regards to their retention in the program at rates similar to the larger UC DPP. The investigators will recruit 80 UCLA undergraduate students. Participants will be asked to complete a brief screening online form to assess eligibility and to collect contact information. The PI and/or Research Assistants (RAs) will reach out to eligible participants to obtain informed consent and enroll them in the pilot trial. The investigators will randomize participants to the tailored DPP cohort vs control cohort. Control participants will be offered the opportunity to participate in the tailored DPP in the following academic year. The tailored DPP intervention will be online and asynchronously. Participants will be asked to complete the intervention lessons on their own time. Each lesson typically takes on average 15 minutes to complete. Control group will receive each intervention materials via e-mail for participants to review on their own time and will receive acceptability surveys. The interventions for the control group will be remote. A research assistant will meet with control participants via Zoom to explain the intervention materials. Control group will receive access to a study habits intervention, alcohol use intervention, and financial literacy intervention. At the end of each quarter (Fall, Winter, and Spring), both control and intervention participants will receive an email with a unique link to a brief REDCap survey to ascertain acceptability of sessions/lessons. Furthermore, participants will complete baseline and 9-month follow-up assessments. Participants will complete a 30 minute questionnaire and height/weight measurements will be collected by a RA. Participants will be asked to self-report weight and physical activity at the end of the fall and winter quarter; data will be collected via brief REDCap survey.
Recruiting
Has No Placebo
University of California, Los AngelesLauren E Wisk, PhD
Have you considered Synjardy clinical trials? We made a collection of clinical trials featuring Synjardy, we think they might fit your search criteria.Go to Trials
Image of Medpace Clinical Pharmaology Unit in Cincinnati, United States.

PATAS for Type 2 Diabetes

18 - 55
All Sexes
Cincinnati, OH
The primary objective of Part 1 of this study is to evaluate safety and tolerability of single subcutaneous (SC) doses of PATAS in healthy subjects. The secondary objective of Part 1 of this study is to determine the pharmacokinetics (PK) of single SC doses of PATAS in healthy subjects. The primary objectives of Part 2 of this study are to evaluate the safety and tolerability of 4 weekly SC doses of PATAS in subjects with T2D; and to determine the PK and pharmacodynamics (PD) of 4 weekly SC doses of PATAS in subjects with T2D. The secondary objectives of Part 2 of this study are to evaluate the potential effect of multiple SC doses of PATAS on markers of glycemic control, as measured by glucose levels, insulin levels, and other metabolomic biomarkers; and to characterize the adverse event (AE) profiles of the various dose levels of PATAS.
Phase 1
Waitlist Available
Medpace Clinical Pharmaology UnitVincent Marion, Ph.D.AdipoPharma LLC
Image of The Worship Center Cristian Church in Birmingham, United States.

Black Impact for Heart Health

18+
Male
Birmingham, AL
The goal of this clinical trial is to evaluate the implementation and effectiveness of the Black Impact program-a church-based cardiovascular health (CVH) intervention-in Black men aged 35-70 who are at risk for heart disease, diabetes, obesity, and related conditions. The main questions this study aims to answer are: * Does participation in the Black Impact program improve cardiovascular health metrics (e.g., blood pressure, cholesterol, blood sugar) and health behaviors among Black men at The Worship Center Christian Church (TWC)? * What factors influence the adoption, delivery, and sustainability of the Black Impact program in a faith-based setting? Researchers will compare an immediate-start intervention group and a delayed-start (waitlist control) group to assess both short-term health outcomes and program implementation factors. Participants will: * Attend a 90-minute weekly session for 24 weeks, including 45 minutes of physical activity led by a certified trainer and 45 minutes of health education delivered by trained coaches. * Receive one-on-one support from a community health worker to reduce barriers to care and engage with primary care. * Complete biometric health screenings and surveys at baseline, 12 weeks, and 24 weeks to assess clinical and behavioral outcomes. * Use a smartwatch, blood pressure cuff, and other tools to track progress in real time. * Participate in exit focus groups or interviews to share feedback about the intervention. * A subset of TWC leaders and interventionists (N=15) will also be interviewed to assess implementation, resource needs, and sustainability. This study uses the RE-AIM framework to assess Reach, Effectiveness, Adoption, Implementation, and Maintenance, and aims to inform scalable strategies for improving CVH among Black men in trusted community settings.
Waitlist Available
Has No Placebo
The Worship Center Cristian Church
Have you considered Synjardy clinical trials? We made a collection of clinical trials featuring Synjardy, we think they might fit your search criteria.Go to Trials
Image of University of British Columbia - Okanagan in Kelowna, Canada.

Estrogen and Testosterone for Gender Differences in Physiology

18 - 40
All Sexes
Kelowna, Canada
Due to historical exclusion of females from research, there are gaps in the understanding of female physiology, how it differs from males, and how sex-specific hormones contribute. As a result, many diagnoses and treatments are based on male physiology and may not be appropriate or effective for females. Females consistently experience greater risk and report worse neurological outcomes in many diseases, including stroke, cardiac arrest, and dementia. As research in females progresses, differences between sexes and changes throughout the lifespan (e.g., puberty, menopause) highlight the importance of understanding the effects of sex and sex-specific hormones on the body. The brain is arguably the most important organ in the body, consuming 20% of the body's total energy. Previous research supports higher blood flow to the brain in females, and research in animals suggests hormones such as estrogen, progesterone, and testosterone are responsible. However, it is extremely difficult to isolate these hormones in humans, due to natural fluctuations (i.e., menstrual cycle). Therefore, the investigators plan to explore the direct role of these sex-specific hormones in regulating blood flow to the brain by blocking hormone production in healthy males and females and giving back testosterone and estrogen, respectively. The investigators will then conduct a range of tests to look at blood flow to the brain at rest and during various stressors. This research will provide crucial insight into how males and females differ in regulation of brain blood flow and inform new treatments and therapies to a wide range of brain injuries and diseases, improving outcomes and reducing the sex disparity in clinical pathways.
Waitlist Available
Has No Placebo
University of British Columbia - OkanaganPhilip Ainslie, PhD
Have you considered Synjardy clinical trials? We made a collection of clinical trials featuring Synjardy, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security